Hiteck(SZ:300683) Chang Jiang Shang Bao·2026-02-12 00:34Core Viewpoint - Hite Bio plans to acquire a 23.08% stake in Beijing Shadong Biotechnology Co., Ltd. for 62.019 million yuan, increasing its ownership to 98.84%, nearly achieving full control over the company and paving the way for the commercialization of its core drug candidate CPT [2][4]. Group 1: Acquisition Details - The acquisition process began in December 2014 with a signed equity acquisition agreement involving multiple stakeholders [3]. - Hite Bio's gradual increase in stake included cash rewards and management of unexercised incentive shares to optimize Beijing Shadong's equity structure [3]. - By April 2024, Hite Bio's stake reached 75.76% through significant share acquisitions, leading to the current acquisition announcement [4]. Group 2: Strategic Importance - The primary motivation for Hite Bio's investment in Beijing Shadong is the core asset, the innovative drug CPT, which is a recombinant biologic for tumor treatment [5]. - Controlling Beijing Shadong allows Hite Bio to directly manage a valuable drug development pipeline, supporting its transition to an innovation-driven biopharmaceutical company [5]. - The acquisition will enable better resource integration and decision-making processes, preparing for CPT's clinical trials and commercialization [5]. Group 3: Future Implications - Successful approval and commercialization of CPT could significantly enhance Hite Bio's revenue and market position in the oncology sector [5]. - Full consolidation of Beijing Shadong into Hite Bio's financial statements will facilitate future planning and value maximization for the drug in global markets [5].